Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 7/20 | 0.57 |
| ▸ | MET | P08581 | 7/20 | 0.57 |
| ▸ | INSR | P06213 | 3/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591233 | 0.94 | AXL (0.66) | AXLFGFR2EGFRMETINSR | |
| SCHEMBL1590967 | 0.93 | AXL (0.67) | AXLEGFRMETINSR | |
| SCHEMBL1592074 | 0.92 | AXL (0.61) | AXLFGFR2EGFRMETINSR | |
| SCHEMBL1591532 | 0.92 | AXL (0.66) | AXLFGFR2EGFRMETLRRK2 | |
| SCHEMBL1591487 | 0.90 | FGFR2 (0.68) | AXLFGFR2MET | |
| SCHEMBL1591171 | 0.90 | AXL (0.63) | AXLFGFR2LRRK2 | |
| SCHEMBL1591169 | 0.86 | AXL (0.63) | AXLEGFRMETINSR | |
| SCHEMBL1591449 | 0.86 | AXL (0.71) | AXLEGFRMETINSR | |
| Hydrochloric Acid SCHEMBL1592105 | 0.85 | AXL (0.71) | AXLEGFRMETINSR | |
| SCHEMBL1590996 | 0.85 | AXL (0.65) | AXLEGFRMETINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | AXL 1/4885FGFR2 348/4885EGFR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.